Cryo Cell International (CCEL) Liabilities and Shareholders Equity (2010 - 2026)

Cryo Cell International has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $60.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 5.43% year-over-year to $60.9 million; the TTM figure through Feb 2026 stood at $250.2 million (down 1.7% YoY), while the FY2025 annual figure was $61.7 million, down 4.56% from the prior year.
• Liabilities and Shareholders Equity declined to $60.9 million in Q1 2026, from $61.7 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for CCEL reached as high as $69.8 million in Q3 2023 and fell as low as $54.8 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $64.4 million (2025), against an average of $63.4 million.
• The widest YoY moves for Liabilities and Shareholders Equity: up 440.93% in 2022, down 47.93% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $64.9 million in 2022, then fell by 0.32% to $64.7 million in 2023, then changed by 0.0% to $64.7 million in 2024, then declined by 4.56% to $61.7 million in 2025, then retreated by 1.37% to $60.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $60.9 million, $61.7 million, and $63.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.